Clinical trial
Olmesartan Medoxomil in Atherosclerosis
NCT00185185 · Sankyo Pharma Gmbh, Industry · Completed
Key facts
| NCT number | NCT00185185 |
|---|---|
| Title | Olmesartan Medoxomil in Atherosclerosis |
| Official title | Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE) |
| Lead sponsor | Sankyo Pharma Gmbh, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension, Atherosclerotic Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Olmesartan medoxomil, Atenolol, Hydrochlorothiazide, olmesartan medoxomil, atenolol |
| Enrollment | 165 |
| Start date | Nov 1, 2001 |
| Completion | Feb 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 14, 2007 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: